Arizona State Retirement System Lowers Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Arizona State Retirement System decreased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 1.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,122 shares of the company’s stock after selling 147 shares during the period. Arizona State Retirement System’s holdings in TransMedics Group were worth $720,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. FMR LLC boosted its stake in TransMedics Group by 42.5% in the 3rd quarter. FMR LLC now owns 4,714,870 shares of the company’s stock worth $258,139,000 after purchasing an additional 1,407,171 shares during the period. BlackRock Inc. grew its stake in TransMedics Group by 2.4% during the second quarter. BlackRock Inc. now owns 2,309,393 shares of the company’s stock valued at $193,943,000 after acquiring an additional 54,776 shares in the last quarter. Vanguard Group Inc. lifted its stake in TransMedics Group by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,814,442 shares of the company’s stock worth $99,341,000 after purchasing an additional 29,798 shares in the last quarter. Summit Partners Public Asset Management LLC boosted its holdings in shares of TransMedics Group by 71.9% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 957,282 shares of the company’s stock valued at $59,083,000 after purchasing an additional 400,255 shares during the last quarter. Finally, Eventide Asset Management LLC increased its holdings in shares of TransMedics Group by 1,271.7% in the third quarter. Eventide Asset Management LLC now owns 925,356 shares of the company’s stock worth $50,663,000 after purchasing an additional 857,895 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $87.24 on Friday. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30. The firm has a market cap of $2.85 billion, a PE ratio of -113.30 and a beta of 1.99. The firm’s 50 day simple moving average is $82.97 and its 200-day simple moving average is $72.98. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $99.63.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Monday, February 26th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.22. The company had revenue of $81.20 million for the quarter, compared to the consensus estimate of $68.49 million. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. TransMedics Group’s quarterly revenue was up 158.6% on a year-over-year basis. During the same period last year, the business posted ($0.21) EPS. As a group, equities analysts predict that TransMedics Group, Inc. will post -0.14 EPS for the current year.

Analyst Ratings Changes

TMDX has been the subject of several research analyst reports. JPMorgan Chase & Co. raised their price target on TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. Piper Sandler assumed coverage on shares of TransMedics Group in a report on Thursday, March 28th. They issued an “overweight” rating and a $95.00 target price for the company. Morgan Stanley upped their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. Finally, Oppenheimer increased their price objective on shares of TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.00.

Insiders Place Their Bets

In other news, CFO Stephen Gordon sold 15,000 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $74.01, for a total value of $1,110,150.00. Following the completion of the sale, the chief financial officer now owns 23,299 shares in the company, valued at approximately $1,724,358.99. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider Tamer I. Khayal sold 2,330 shares of the firm’s stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $90.09, for a total transaction of $209,909.70. Following the sale, the insider now owns 14,375 shares of the company’s stock, valued at $1,295,043.75. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Stephen Gordon sold 15,000 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $74.01, for a total transaction of $1,110,150.00. Following the completion of the transaction, the chief financial officer now owns 23,299 shares of the company’s stock, valued at $1,724,358.99. The disclosure for this sale can be found here. Insiders have sold a total of 119,408 shares of company stock worth $10,182,881 in the last three months. Corporate insiders own 6.70% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.